APIS Assay Technologies in Manchester has acquired New York-based start-up Beogenomics for an undisclosed sum.
The specialist software developer works across Bioinformatics and Artificial Intelligence (BIOX). Using in-house and cloud based computing resources, it helps companies construct and run analysis pipelines and develop software tools for genomic data.
It will be integrated into Manchester-based APIS and support the launch of a new BIOX service.
“We are delighted to announce our acquisition of Beogenomics, which offers strong operational and cultural fits. We look forward to welcoming the talented team and working together to expand our BIOX capacity internally, and build out a new, discrete, and externally-facing service line,” said Dr Joachim Schorr, CEO of APIS
Ian Kavanagh, COO of APIS added that the move would enable them to “more effectively capture the exciting opportunities presented in the bioinformatics space.”
